scholarly journals Clinical guidelines for cryosupernatant transfusions

2020 ◽  
Vol 65 (3) ◽  
pp. 351-359
Author(s):  
G. M. Galstyan ◽  
T. V. Gaponova ◽  
F. S. Sherstnev ◽  
A. A. Kupryashov ◽  
N. I. Olovnikova ◽  
...  
Keyword(s):  
Factor Viii ◽  
Antithrombin Iii ◽  
Fresh Frozen Plasma ◽  
Blood Component ◽  
Factor Viii Inhibitor ◽  
Factor V ◽  
Fresh Frozen ◽  
Viii Inhibitor ◽  
Von Willebrand ◽  
Frozen Plasma

Introduction. Cryosupernatant is blood component. Cryosupernatant is the supernatant plasma removed during the preparation of cryoprecipitate. Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of Cryosupernatant. General fi ndings. In comparison with fresh frozen plasma (FFP) and cryoprecipitate, Cryosupernatant plasma is depleted in factor VIII, fi brinogen factor von Willebrand (VWF). Cryosupernatant is defi cient in high molecular weight multimers of VWF, but contains VWF metalloproteinase. The concentrations of factor V, antithrombin III, albumin and immunoglobulins are the same as in FFP and cryoprecipitate. The indications for Cryosupernatant transfusions are massive blood loss in patients with factor VIII inhibitor, plasma exchange in patients with thrombotic thrombocytopenic purpura. For children the doses of Cryosupernatant should be 10-15 mL/kg.

scholarly journals INFLUENCE OF ABO BLOOD GROUP ON FACTOR VIII AND FACTOR V LEVELS IN FRESH FROZEN PLASMA

2020 ◽  
Vol 42 ◽  
pp. 404-405
Author(s):  
C.M. Wink ◽  
J.S. Palaoro ◽  
D. Glimm ◽  
A.A.C. Araujo ◽  
C.S.R. Araujo
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Fresh Frozen Plasma ◽  
Abo Blood Group ◽  
Factor V ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals Successful Pregnancy in a Patient with Combined Deficiency of Factor V and Factor VIII

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Ahmed Ghassan El Adib ◽  
Farah Majdi ◽  
Mohamed Othmane Dilai ◽  
Hamid Asmouki ◽  
Ahlam Bassir ◽  
...  
Keyword(s):  
Factor Viii ◽  
Fetal Monitoring ◽  
Fresh Frozen Plasma ◽  
Factor V ◽  
Successful Pregnancy ◽  
Fresh Frozen ◽  
Factor Viii Concentrates ◽  
Low Levels ◽  
Frozen Plasma ◽  
Combined Deficiency

Inherited combined factor V and factor VIII deficiency (F5F8D) is autosomal recessive transmission disorder. Epistaxis, postsurgical bleeding, and menorrhagia are the most common symptoms. The risk of miscarriage and placental abruption is consequent. We report a case of successful pregnancy in a patient with F5F8D. 20-year-old woman, born of consanguineous parents, third gestate, first parity, two miscarriages, admitted for child birth of a spontaneous pregnancy estimated at 38 weeks and was diagnosed with F5F8D. At admission, patient was hemodynamically stable, with good obstetric conditions. The biologic results showed low levels of PT (52%), factor V (7%), and factor VIII (5%), and the activated partial thromboplastin time was prolonged (68,6%). Parturient was admitted in intensive care unit, maternal and fetal monitoring was performed. Fresh frozen plasma (FFP) and factor VIII concentrates were perfused at the induction of labor. Analgesia used fentanyl titration. The delivery gave birth to a newborn male, with Apgar 10/10 and 3000 g. The puerperium was simple without any important bleeding. Laboratory tests for the newborn were acceptable. Little literature is available on this subject and there are no guidelines available concerning pregnancy; we chose to prescribe a combination of factor VIII concentrate and FFP in pre-, per- and postpartum. The same protocol was successfully used in a patient before dental extraction and prostatectomy. Vaginal delivery is possible, as our case. Management by multidisciplinary team is recommended.

Treatment of rare factor deficiencies other than hemophilia

Blood ◽  
2019 ◽  
Vol 133 (5) ◽  
pp. 415-424 ◽  
Author(s):  
Marzia Menegatti ◽  
Flora Peyvandi
Keyword(s):  
Fresh Frozen Plasma ◽  
Von Willebrand Disease ◽  
Factor V ◽  
Number Of Patients ◽  
Fresh Frozen ◽  
Life Threatening ◽  
Tissue Factor Pathway ◽  
Von Willebrand ◽  
Frozen Plasma

Abstract The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages. RCDs are characterized by a wide variety of symptoms, from mild to severe, which can vary significantly from 1 disease to another and from 1 patient to another. The most typical symptoms of all RCDs are mucosal bleedings and bleeding at the time of invasive procedures, whereas other life-threatening symptoms such as central nervous system bleeding and hemarthroses are mostly present only in some deficiencies (afibrinogenemia, FX, and FXIII). At variance with hemophilia A and B and von Willebrand disease, RCDs are much less prevalent, ranging from 1 case in 500 000 to 1 in 2 million in the general population. Their clinical heterogeneity associated with the low number of patients has led to a delay in the development of appropriate therapies. Indeed, a similar heterogeneity can also be found in the treatment products available, ranging from the specific recombinant proteins to treat FVII- and FXIII-deficient patients to the complete absence of specific products to treat patients with FII or FV deficiencies, for whom prothrombin complex concentrates or fresh frozen plasma are, to date, the only option. The recent development of novel hemostatic approaches for hemophilia, such as the use of nonsubstitutive therapy as RNA interference, anti–tissue factor pathway inhibitor, and the gene therapy aimed at improving the patient’s quality of life may also have an important role in the treatment of patients with RCDs in the future.

The Recovery of Factor VIII from Fresh-Frozen, Indated and Outdated Human Plasma

1976 ◽  
Vol 36 (01) ◽  
pp. 071-077 ◽  
Author(s):  
Daniel E. Whitman ◽  
Mary Ellen Switzer ◽  
Patrick A. McKee
Keyword(s):  
Factor Viii ◽  
Polyacrylamide Gel Electrophoresis ◽  
Sodium Dodecyl ◽  
The United States ◽  
Fresh Frozen Plasma ◽  
Red Cross ◽  
Random Samples ◽  
Fresh Frozen ◽  
Factor Viii Concentrates ◽  
Frozen Plasma

SummaryThe availability of factor VIII concentrates is frequently a limitation in the management of classical hemophilia. Such concentrates are prepared from fresh or fresh-frozen plasma. A significant volume of plasma in the United States becomes “indated”, i. e., in contact with red blood cells for 24 hours at 4°, and is therefore not used to prepare factor VIII concentrates. To evaluate this possible resource, partially purified factor VIII was prepared from random samples of fresh-frozen, indated and outdated plasma. The yield of factor VIII protein and procoagulant activity from indated plasma was about the same as that from fresh-frozen plasma. The yield from outdated plasma was substantially less. After further purification, factor VIII from the three sources gave a single subunit band when reduced and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. These results indicate that the approximately 287,000 liters of indated plasma processed annually by the American National Red Cross (ANRC) could be used to prepare factor VIII concentrates of good quality. This resource alone could quadruple the supply of factor VIII available for therapy.

Factors Affecting Transfusion of Fresh Frozen Plasma, Platelets, and Red Blood Cells During Elective Coronary Artery Bypass Graft Surgery

2003 ◽  
Vol 127 (4) ◽  
pp. 415-423
Author(s):  
Randal Covin ◽  
Maureen O'Brien ◽  
Gary Grunwald ◽  
Bradley Brimhall ◽  
Gulshan Sethi ◽  
...  
Keyword(s):  
Blood Cells ◽  
Prediction Models ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Fresh Frozen Plasma ◽  
Blood Component ◽  
Artery Bypass Graft ◽  
Blood Components ◽  
Fresh Frozen ◽  
Frozen Plasma

Abstract Context.—The ability to predict the use of blood components during surgery will improve the blood bank's ability to provide efficient service. Objective.—Develop prediction models using preoperative risk factors to assess blood component usage during elective coronary artery bypass graft surgery (CABG). Design.—Eighty-three preoperative, multidimensional risk variables were evaluated for patients undergoing elective CABG-only surgery. Main Outcome Measures.—The study endpoints included transfusion of fresh frozen plasma (FFP), platelets, and red blood cells (RBC). Multivariate logistic regression models were built to assess the predictors related to each of these endpoints. Setting.—Department of Veterans Affairs (VA) health care system. Patients.—Records for 3034 patients undergoing elective CABG-only procedures; 1033 patients received a blood component transfusion during CABG. Results.—Previous heart surgery and decreased ejection fraction were significant predictors of transfusion for all blood components. Platelet count was predictive of platelet transfusion and FFP utilization. Baseline hemoglobin was a predictive factor for more than 2 units of RBC. Some significant hospital variation was noted beyond that predicted by patient risk factors alone. Conclusions.—Prediction models based on preoperative variables may facilitate blood component management for patients undergoing elective CABG. Algorithms are available to predict transfusion resources to assist blood banks in improving responsiveness to clinical needs. Predictors for use of each blood component may be identified prior to elective CABG for VA patients.

scholarly journals Case Report on Management of Combined Factor V and factor VIII Deficiency during Pregnancy

2021 ◽  
pp. 1-2
Author(s):  
Dr. Kirti Solanki ◽  
Dr. Swati Kochar ◽  
Dr. Shweta Choudhary ◽  
Dr. Priyanka Gaur ◽  
Dr. Krishna Krishna
Keyword(s):  
Factor Viii ◽  
Post Partum ◽  
Autosomal Recessive Disorder ◽  
Fresh Frozen Plasma ◽  
Factor V ◽  
Bleeding Tendency ◽  
Factor Viii Deficiency ◽  
Risk Of Bleeding ◽  
Increased Risk ◽  
Fresh Frozen

Combined factor V and factor VIII deficiency (CF5F8D) is a rare autosomal recessive disorder associated with mild to moderate risk of bleeding tendency. These patients have an increased risk of bleeding after surgical procedures. Pregnant women are at increased risk of having a miscarriage, placental abruption, or post partum hemorrhage. Management of these patients requires the replacement of deficient factors. We are reporting a case of management of a 31-year old second gravida female with combined factor V and factor VIII deficiency, who was transfused with fresh frozen plasma before and during labor to prevent bleeding episodes.

Sign in / Sign up

Export Citation Format

Share Document